Company intelligence / Profile preview

FUTRUE

Munich*, Bavaria*, Germanybacktothefuture.com ↗

Ownership: Private
Development stage: Other

Overview

FUTRUE has developed innovative therapies such as the cannabinoid-based pain medication VER‑01, which represents a significant milestone toward treating chronic pain. The company also launched Kijimea for irritable bowel syndrome, now a market leader. Their R&D arm aims to halve clinical trial times and costs compared to industry standards

Therapeutic areas: GastroenterologyNeurology
Modalities: Small moleculeBiologic (including cannabinoid-based drugs, probiotics)
Industry: Biotech

Drug pipeline

4 assets

Mikro7

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; focus appears on internal innovation and subsidiary structure.

Beyond the preview

Go deeper on FUTRUE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FUTRUE.

Explore the full profile